Mostrar registro simples

dc.contributor.authorD'Almeida, Karina Sanches Machadopt_BR
dc.contributor.authorSilva, Eneida Rejane Rabelo dapt_BR
dc.contributor.authorSouza, Gabriela Corrêapt_BR
dc.contributor.authorTrojahn, Melina Mariapt_BR
dc.contributor.authorBarilli, Sofia Louise Santinpt_BR
dc.contributor.authorMansson, Jessica V.pt_BR
dc.contributor.authorBiolo, Andreiapt_BR
dc.contributor.authorRohde, Luis Eduardo Paimpt_BR
dc.contributor.authorClausell, Nadine Oliveirapt_BR
dc.contributor.authorSilva Neto, Luís Beck dapt_BR
dc.date.accessioned2015-02-20T02:20:12Zpt_BR
dc.date.issued2014pt_BR
dc.identifier.issn1745-6215pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/110241pt_BR
dc.description.abstractBackground: Although half of all patients with heart failure (HF) have a normal or near-normal ejection fraction and their prognosis differs little from that of patients with a reduced ejection fraction, the pathophysiology of HF with preserved ejection fraction (HF-PEF) is still poorly understood, and its management poorly supported by clinical trials. Sodium and fluid restriction is the most common self-care measure prescribed to HF patients for management of congestive episodes. However, its role in the treatment of HF-PEF remains unclear. This trial seeks to compare the effects of a sodium- and fluid-restricted diet versus an unrestricted diet on weight loss, neurohormonal activation, and clinical stability in patients admitted for decompensated HF-PEF. Methods/Design: This is a randomized, parallel trial with blinded outcome assessment. The sample will include adult patients (aged ≥18 years) with a diagnosis of HF-PEF admitted for HF decompensation. The patients will be randomized to receive a diet with sodium and fluid intake restricted to 0.8 g/day and 800 mL/day respectively (intervention group) or an unrestricted diet, with 4 g/day sodium and unlimited fluid intake (control group), and followed for 7 days or until hospital discharge. The primary outcome shall consist of weight loss at 7 days or discharge. The secondary outcome includes assessment of clinical stability, neurohormonal activation, daily perception of thirst and readmission rate at 30 days. Discussion: Assessment of the effects of sodium and fluid restriction on neurohormonal activation and clinical course of HF-PEF can promote a deeper understanding of the pathophysiology and progression of this complex syndrome.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofTrials. London. Vol. 15 (2014), 347, 6 p.pt_BR
dc.rightsOpen Accessen
dc.subjectInsuficiência cardíacapt_BR
dc.subjectHeart failureen
dc.subjectDietary sodiumen
dc.subjectSódio na dietapt_BR
dc.subjectEnsaio clínico controlado aleatóriopt_BR
dc.subjectPreserved ejection fractionen
dc.subjectRandomized clinical trialen
dc.titleEffect of fluid and dietary sodium restriction in the management of patients with heart failure and preserved ejection fraction : study protocol for a randomized controlled trialpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000938467pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples